Twelve ASA physical status I-III patients were enrolled in a double-blind, prospective, randomized, three-way, withinpatient Electroconvulsive therapy (ECT) may produce intense stimulation of the central nervous system resulting in hypertension and tachycardia, t'2 The haemodynamic effects of ECT could place the patient with coronary or cerebrovascular disease at risk of myocardial ischaemia/ infarction or stroke. 3-5 Esmolol hydrochloride (Brevibloc) is a new ultra-short acting betal selective adrenergic blocking agent. Esmolol bolus 6 and infusion 7 have been found to be effective in attenuating the cardiovascular response to ECT. However, comparison of the effects of different standardized bolus doses and their effect on the
with esmolol 200 mg resulted in a significantly shorter mean seizure duration than with placebo. As the 200 mg dose caused a shorter seizure duration and the haemodynamic effects of I00 mg and 200 mg doses were similar, it was concluded that the I00 mg esmolol bolus dose was the better dose for ECT.
Douze patients de classe ASA I-III ont particip~ d trois sdances varides de notre (tude randomisde d double insu sur l'effet de deux doses d'esmolol en bolus (100 et 200 mg) sur les variables hdmodynamiques et la durde des convulsions assocides at•r dlectrochocs ( EC ). On leur injectait I'esmolol ou un placdbo une minute avant I' induction de l'anesthdsie puis detzx minutes avant I'EC. Comparativement au placdbo, les deax doses d' esmolol dmoussaient significativement les augmentations maxinlales de la frdquence cardiaque, de la tension artdrielle et du produit pouls-pression, les r~duisant respectivement de 23 +-3%, 17 +-7% et 40 +-9%pour la dose de I00 mg et de 25 +-. 3%, 19 +-3% et 42 +--5% pour celle de 200 mg. Avant et aprds rEC, les valeurs hdmodynamiques assocides aloc deux doses d'esmolol dtaient comparables. Toutefois, avecla dose de 200 rag, les convulsions duraient significativement moins longtemps qu' avec le placdbo. Dans un contexte d'EC, une dose de I00 mg d' esmolol est donc prdfdrable.
Electroconvulsive therapy (ECT) may produce intense stimulation of the central nervous system resulting in hypertension and tachycardia, t'2 The haemodynamic effects of ECT could place the patient with coronary or cerebrovascular disease at risk of myocardial ischaemia/ infarction or stroke. 3-5 Esmolol hydrochloride (Brevibloc) is a new ultra-short acting betal selective adrenergic blocking agent. Esmolol bolus 6 and infusion 7 have been found to be effective in attenuating the cardiovascular response to ECT. However, comparison of the effects of different standardized bolus doses and their effect on the 7 '05   TABLE I Exclusion criteria Pregnant women Less than 21 yr AV conduction block greater than I ~ Systolic BP < 100 mmHg or diastolic BP < 50 mmHg Heart rate < 50 bpm Bronchospasm or bronchial asthma Drug allergy or idiosyncracy to beta-adrenergic drugs Experimental drugs within two weeks Patients on beta blockers or calcium channel blockers (i) compare the effect of two standardized esmolol bolus doses (100 and 200 rag) on heart rate (HR) and blood pressure (BP), and (ii) investigate the effect of these doses on seizure duration during ECT.
Methods
This study was approved by the Human Subjects Committee of our institution and written informed consent was obtained from each patient. The study patients were ASA physical status 1, I1, or ill and selected from those receiving general anaesthesia for ECT. Exclusion criteria are listed in Table I .
All patients received premedication with glycopyrrolate 0.3 mg im 30-60 rain before ECT. The HR was monitored by ECG, BP by manual cuff, oxygen saturation by pulse oximeter, carbon dioxide by end-tidal CO2 monitor, and seizure duration by EEG. Recording limes for HR and BP did not occur during the actual seizure period. All patients received esmolol 100 mg, 200 rag, and placebo (normal saline) in a prospeclive, randomized, double-blind, three-way, within-patient, crossover design. Thus, each patient served as his or her own control.
Esmolol (or placebo) was administered at time zero by hand-held bolus over 15 sec, one minute before induction of anaesthesia and exactly two minutes before ECT. Anaesthesia was induced with methohexitone 1.0 mg. kgand succinylcholine 0.75 mg.kg -t. The HR and BP were recorded pre-bolus and every minute for ten minutes post-bolus, then at 12, 15, 20, 25 and 40 min following bolus injection. Three to five days later the patients crossed over to the alternative treatment and repeated the procedures outlined above.
A monitored electroconvulsive therapy apparatus (MECTA) machine was used to administer the electrical shock current charge. All ECT shocks were unilateral. All patients received the same electrical shock current for each ECT and received only one shock per treatment (70 Hz, with i.5 msec pulse width and 2.0 see duration).
Statistical analysis
Data were evaluated as per cent change from pre-bolus baseline values. All statistical analyses were performed using the statistical analysis system. 8 Analysis of variance (in a crossover model) was used to analyze HR, BP, rate-pressure product (RPP) and seizure duration at the successive measurement times. T tests, using the pooled mean square error from the variation among patients within the three treatment groups, were used to determine the relation among the treatments. A P < 0.05 level was set for statistical significance.
Results
Of the 12 patients studied, the mean (-SD) age was 52 +-19 yr (range 23-78) and mean weight was 70 ---13 kg (range 54-95). As this was a within-patient comparison, 12 patients were in each study group. Concomitant patient medications are listed in Table 1I FIGURE I Heart rate per cent change (mean • SEM).
respectively. There was a significant difference in RPP between the 100 mg esmolol dose and placebo for up to four minutes post-ECT and up to 13 minutes post-ECT for the 200 mg dose (Figure 3 ). RPP baseline control values for placebo, 100 mg, and 200 mg esmolol doses were I1,000 ---600, 10,900 -' &-700, and 12,700 +-800 respectively. Esmolol bolus had a more significant effect on HR than on MAP. There were no significant differences between the two doses with respect to HR, MAP, RPP or seizure duration. However, seizure duration was significantly shorter with 200 mg of esmolol compared with placebo (Table I11) . No arrhythmias or adverse experiences occurred.
Discussion
Electroconvulsive therapy is an important modality in the treatment of depression, especially in patients resistant to pharmacological therapy. Electroconvulsive therapy accounts for approximately 4% of psychiatric admissions in the United States 1'9 with about 100,000 treatments administered annually, s'l~ A hyperdynamic cardiovascular response occurs as a result of autonomic nervous system stimulation. Parasympathetic discharge occurs immediately with sympathetic discharge following within seconds. Hypertension, tachycardia, and an increase in cardiac output often occur. 1,2 Although rare, cardiovascular complications are the main cause of death during ECT with a mortality rate of 0.03% of patients treated, and 0.0045% of individual ECT treatments. 2'5'11 This is higher than the often quoted overall anaesthetic mortality of of I: 10,000. i2 Morbidity and mortality during ECT is usually secondary to myocardial ischaemia/infarction or stroke. 2-5 Patients who are elderly, have chronic hypertension, or pre-existing cardiac disease are especially at risk for an adverse event occurring in the peri-ECT period. 3 '4 Similar to techniques used for tracheal intubation, many pharmacological methods have been used in at- tempting to blunt the haemodynamic effects of ECT. These include oral clonidine, 13 intranasal nifedipine, ~4 nitroglycerin ointment, Is iv sodium nitroprusside, '3 methohe xitone, ,6 thiopentone, and propofol, 16 trimethaphan, 17 propranolol, is..9 hydralazine, 19 labetalol,20 and diazoxide. 2' Both continous infusion and bolus techniques have been used. Although numerous techniques are available, many have side-effects with durations of action longer than the short ECT stimulus itself. The ideal agent and/or technique for attenuating the hyperdynamic response of ECT would be convenient, easy to prepare and administer, rapid-acting, brief, non-toxic, and have minimal or no side-efficts. Ideally, duration of action should correspond to the period of time the drug and/or technique is needed.
Esmolol hydrochloride is an ultrashort-acting, beta-one selective blocker with a distribution half-life of two minutes and an elimination half-life of nine minutes, z2 Esmolol appears quite suitable for use during a short-lived stress such as tracheal intubation or ECT. Administration of esmolol by bolus and infusion has been found to be effective in blunting the haemodynamic effects of laryngoscopy and intubation 23 as well as intra-operative z4 and postoperative 25 stresses.
Previous dosing regimens of esmolol have been confusing and complex. Esmolol originally required dilution of a 2.5 g, 10 ml ampule (250 rag. ml-' in 250 ml of D5W to obtain a 10 mg. ml -I solution). The manufacturer developed a 100 mg vial (10 mg. ml -t) for convenience and ease of administration. Our selection of 100 and 200 mg bolus doses was selected on this basis (one and two unit vials respectively). A 100 mg and 200 mg dose in a 70 kg patient corresponds to 1.43 mg. kg-i and 2.86 mg. kg-i respectively. Esmolol can effectively be administered as a set dose rather than adjusting for patient weight. 22 However, if one desires, a mg. kg -I dose can also be administered.
Proper bolus timing and dosage in relation to the stimulus is important. The esmolol bolus should be given within two minutes of the expected stimulus 26 since a bolus dose given three to four minutes before the stimulus may be too early. 27 We administered esmolol one minute before anaesthesia induction and exactly two minutes before ECT shock. In our experience, esmolol can also be administered immediately after methohexitone and succinylcholine within two minutes before ECT shock and be equally effective.
Comparisons between this bolus study and our previous infusion study 7 can be made. In the esmolol infusion study, HR remained below baseline for the entire study. Also, mean MAP increased to 20% above baseline compared with 43% in the "no esmolol" group. In this bolus study ( Figures I and 2 ), HR remained below baseline for one and four minutes post-ECT for the 100 mg and 200 mg esmolol bolus doses respectively. The mean MAP increased to a maximum of 30% and 23% above baseline for the 100 mg and 200 mg doses respectively compared with a maximum 54% increase above baseline for placebo. The increase in MAP was similar for both the bolus and infusion methods. As seen in Figures I and 2 , esmolol's effect is primarily on HR (negative chronotropic effect) and secondarily on BP. This effect was also seen in the esmolol infusion study. The decrease in cardiac output and thus BP is likely secondary not only to decreases in HR but also from decreases in stroke volume secondary to a negative inotropic effect. 7 The RPP paralleled the course of HR and MAP (Figure 3 ). While esmolol bolus is more convenient and easier to administer than the infusion method, a more brief control of HR also occurs. Repeat bolus doses may be required post-ECT if further control of HR and BP is desired. Esmolol infusion produces better HR and BP control for a longer time than bolus administration.
The therapeutic effect of ECT depends on a cerebral seizure. There appears to be a dose-response concept to the therapeutic efficacy of ECT with an optimal therapeutic outcome occurring if the seizure lasts approximately 30 sec or longer. 2s Seizure duration during ECT is influenced by the age and sex of the patient, electrode placement, type of electrical stimulus producing the seizure, blood gas tensions (PO2 and CO2), number of treatments already completed, and choice and dose of induction agent. 29 A within-patient crossover design was chosen to eliminate these variables. An end-tidal CO2 monitor was used to keep CO2 approximately 28-30 mmHg and a pulse oximeter was used to keep oxygen saturation 98-100%.
Esmolol bolus appears to have a dose-related effect on seizure duration (Table I11 ). However, it should also be stressed that for both the 100 and 200 mg bolus doses, seizure durations were longer (40 and 45 sec, respectively) than the recommended 30 sec minimum. In summary, both esmolol 100 mg and 200 mg bolus doses were found effective in blunting the haemodynamic response during and following ECT in ASA physical status I, I1, and 111 patients. As the 200 mg dose caused a shorter seizure duration and the haemodynamic effects of the 100 and 200 mg doses were similar, the 100 mg esmolol bolus dose was considered to be the better dose for ECT.
